StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Free Report) in a research report sent to investors on Monday. The firm issued a buy rating on the biopharmaceutical company’s stock.
Acorda Therapeutics Price Performance
The company has a debt-to-equity ratio of 3.07, a current ratio of 0.33 and a quick ratio of 0.26. The business has a 50 day simple moving average of $10.27 and a two-hundred day simple moving average of $11.87. The stock has a market capitalization of $820,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.40. Acorda Therapeutics has a 52 week low of $0.61 and a 52 week high of $24.20.
About Acorda Therapeutics
Featured Articles
- Five stocks we like better than Acorda Therapeutics
- Insider Trading – What You Need to Know
- 3 CEO-Led Turnaround Stocks You Can Still Buy
- 3 Tickers Leading a Meme Stock Revival
- 3 Value Stocks You Can Buy Before They Become Big
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Chinese Stocks Stage Impressive Rebound
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.